IntroductionMultiple myeloma (MM) is a malignant neoplasm characterized by clonal proliferation of plasma cells in the bone marrow (BM). This disease accounts for approximately 2% of all cancer deaths and nearly 20% of deaths caused by hematologic malignancies. 1 Although allogeneic stem-cell transplantation 2-5 occasionally cures these patients, and drugs such as thalidomide, lenalidomide, and bortezomib have improved outcomes, 6 high-dose chemotherapy followed by autologous stem-cell transplantation (ASCT) 7 still appears to be the best treatment for patients up to 70 years of age. However, the great majority of patients with MM are incurable due to the persistence of minimal residual disease. 8,9 Thus, novel modalities complementing or improving current treatment options are needed.Natural killer (NK) cells are cytotoxic lymphocytes that lyse certain tumor-and virus-infected cells without any prior stimulation or immunization. 10 The cytotoxic activity of NK cells is tightly controlled by a balance between activating and inhibitory signals from receptors on the cell surface. A main group of receptors that inhibit NK-cell activation is the inhibitory killer immunoglobulinlike receptors (KIRs). Upon recognition of self-MHC class I molecules on target cells, these receptors deliver an inhibitory signal that stops the activating signaling cascade, sparing cells with normal MHC class I expression from NK cell-mediated lysis. Activating receptors include the natural cytotoxicity receptors (NCRs) and NKG2D, all of which push the balance toward cytolytic action through engagement with separate ligands on the target cell surface. 11,12 This role of NK cells indicates their possible use for adoptive immunotherapeutic strategies, in particular against malignancies that express low levels of MHC class I molecules. 13 The aim of this study was to investigate whether, and under what conditions, NK cells from patients with MM can be expanded numerically using good manufacturing practice (GMP)-compliant components. Furthermore, we aimed to investigate if NK cells expanded ex vivo could target autologous MM cells and thus prove to be favorable candidates for immunotherapeutic approaches against MM. Methods Patients and acquisition of patient materialPeripheral blood and BM samples from 7 newly diagnosed patients at different stages of MM were included in this study. The patients were admitted to the Department of Hematology, Karolinska University Hospital Huddinge, Stockholm, Sweden. The study was approved by the south Stockholm research ethics committee. Informed consent was obtained from all patients in accordance with the Declaration of Helsinki. Patients' characteristics at the time of blood and BM sampling are given in Table 1.Peripheral blood mononuclear cells (PBMCs) as well as BM mononuclear cells (BMMCs) were isolated by gradient centrifugation, using Lymphoprep (Axis-Shield, Oslo, Norway). PBMCs and BMMCs were washed twice with phosphate-buffered saline (PBS; Gibco, Grand Island, NY), and cell viability was assessed...
We demonstrate that fusion proteins consisting of the her-COS cells transfected with tk alone. Tumours established pes simplex virus (HSV) transport protein VP22 linked in in mice with neuroblastoma cell lines expressing VP22-tk frame to HSV thymidine kinase (tk) retain the ability to be regressed upon administration of ganciclovir. Furthermore transported between cells. In vivo radiolabelling experitumours established from 50:50 mixtures of VP22-tk transments and in vitro assays show that the fusion proteins duced and nontransduced cells also regressed while no also retain tk activity. When transfected COS cells, acting significant effect was observed in similar experiments with as a source of the VP22-tk chimera, were co-plated on to cells transduced with tk alone. VP22 mediated transport gap junction-negative neuroblastoma cells, ganciclovir may thus have application in a clinical setting to amplify treatment induced efficient cell death in the recipient neurodelivery of the target protein in enzyme-prodrug protocols. blastoma cell monolayer. No such effect was observed with
Human embryonic stem cell (hESC) lines, after directed differentiation, hold the greatest potential for cell transplantation treatment in many severe diseases. Good manufacturing practice (GMP) quality, defined by both the European Medicines Agency and the Food and Drug Administration, is a requirement for clinical-grade cells, offering optimal defined quality and safety in cell transplantation. Using animal substance-free culture media, feeder cells or feeder-free matrix in derivation, passaging, expansion and cryopreservation procedures, immune reactions against animal proteins in the cells, and infection risk caused by animal microbes can be avoided. It is also possible to apply GMP to animal components if no better options are available. In recent production of GMP-quality hESC lines, feeder cells had been cultured in fetal bovine serum, and the medium supplemented with an animal protein containing a serum replacement component. Using embryos cultured in a GMP laboratory, isolating the inner cell mass mechanically, deriving lines on human feeder cells originally cultured in xeno-free medium in a GMP laboratory, and using xeno-free media for derivation and culture of hESC lines themselves, GMP-quality xeno-free hESC lines could be established today. Human serum is a xeno-free component available today, but many chemically defined media are under development.
Insights into the molecular basis for natural killer (NK) cell recognition of human cancer have been obtained in recent years. Here, we review current knowledge on the molecular specificity and function of human NK cells. Evidence for NK cell targeting of human tumors is provided and new strategies for NK cell-based immunotherapy against human cancer are discussed. Based on current knowledge, we foresee a development where more cancers may be subject to treatment with drugs or other immunomodulatory agents affecting NK cells, either directly or indirectly. We also envisage a possibility that certain forms of cancers may be subject to treatment with adoptively transferred NK cells, either alone or in combination with other therapeutic interventions.
The chimeric state after allogeneic hematopoietic stem cell transplantation provides a platform for adoptive immunotherapy using donor-derived immune cells. The major risk with donor lymphocyte infusions (DLIs) is the development of graft-versus-host disease (GvHD). Development of new DLI products with antitumor reactivity and reduced GvHD risk represents a challenging task in cancer immunotherapy. Although natural killer (NK) and NK-like T cells are promising owing to their antitumor activity, their low concentrations in peripheral blood mononuclear cells reduces their utility in DLIs. We have recently developed a system that allows expansion of clinical-grade NK and NK-like T cells in large numbers. In this study, the safety of donor-derived long-term ex vivo-expanded human NK and NK-like T cells given as DLIs was investigated as immunotherapy for cancer in five patients following allogeneic stem cell infusion. Infusion of the cells was safe whether administered alone or with IL-2 subcutaneously. No signs of acute GvHD were observed. One patient with hepatocellular carcinoma showed markedly decreased serum alpha-fetoprotein levels following cell infusions. These findings suggest that the use of ex vivo-expanded NK and NK-like T cells is safe and appears an attractive approach for further clinical evaluation in cancer patients.
B-cell chronic lymphocytic leukemia (B-CLL) is the most common leukemia in the Western world. It is currently an incurable disease, making new treatment options such as immunotherapy desirable. Monoclonal antibodies (Mabs) to surface antigens of the tumor cell is one option. Administration of cytotoxic cells such as natural killer (NK) and natural killerlike T (NKT) cells expanded in vitro might be a useful treatment modality alone or in combination with MAbs. A limiting step in the development of successful cellular immunotherapy has been the availability of appropriate cytotoxic cells. Here, we report the feasibility of expanding populations of the human killer cells, CD3ÀCD56 þ NK and CD3 þ CD56 þ NKT cells, from peripheral blood mononuclear cells (PBMCs) of B-CLL patients. The influence of tumor B cells on the in vitro expansion of killer cells was assessed by depleting B cells from PBMCs by microbead separation before culture. The 21-day cultures from both B-cell-and non-B-cell-depleted PBMC showed a marked expansion of NK cells, and also of T cells, among which almost half had the NKT phenotype. Depletion of B cells before culture did not change the expansion rates of NK and NKT cells significantly. In patients with progressive B-CLL, NK cell expansion capacity was improved after fludarabine treatment when compared to samples obtained before treatment. Repeated samples of PBMCs from individual untreated patients with both indolent and progressive disease cultured under identical conditions gave similar NK cell expansion rates. Expanded killer cell populations had cytotoxic function against the NK-sensitive target K562 cell line and expressed high levels of Granzyme B. From our studies, we conclude that NK cells as well as NKT cells from the peripheral blood of B-CLL patients can be expanded, and that these cells have cytotoxic capacity.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.